AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)Zacks Investment Research • 07/01/26
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readoutProactive Investors • 06/26/26
For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.WSJ • 06/24/26
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer CareBusiness Wire • 06/24/26
The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffsWSJ • 06/19/26
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 06/18/26
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?Zacks Investment Research • 06/16/26
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancerBusiness Wire • 06/12/26
Astrazeneca (AZN) Outperforms Broader Market: What You Need to KnowZacks Investment Research • 06/11/26
BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)Accesswire • 06/11/26
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?Zacks Investment Research • 06/09/26